BIEL/Electrome: The Next UNICORN / $1B Startup (400% PPS Surge So Far, Better Than 99.9% of All Stocks!)
The Medvi Playbook Is Repeating — But With a Bigger Market and Stronger Tailwinds
The conversation around BIEL is still stuck in the past — but the past is no longer relevant (except for the $40M+ tax-loss carryforward that makes the first $40M profit tax-free). The company that produced the 2024–2025 financials is not the company that exists today.
The pivot is complete.
The model has changed.
The market is only beginning to understand the scale of what’s unfolding.
This is the official beginning of the new story.
1. The 2024–2025 Financials Are Irrelevant — They Belong to the Old Book. Yes, 2025 revenue ticked up slightly and COGS dropped sharply, but:
These numbers reflect the pre-Electrome, pre-Haleon, pre-Veterinary era.
They are the last pages of the legacy standalone device seller model.
They have zero predictive value for the OEM future.
BIEL is no longer a consumer gadget company — it is now the exclusive hardware engine for an AI-native therapeutics ecosystem across:
human health
veterinary health
global consumer health
This is the Intel Inside transformation:
Electrome AI = the brain.
BIEL PEMF hardware = the engine.
The pivot just happened — so historical revenue is meaningless.
2. The OEM Future Is Measured in Millions — Not Thousands
BIEL now has three independent OEM engines, each with multi-million-dollar trajectories:
OEM Engine #1 — Human Health (Electrome)
PAINKILLER™ launch: $0.75M–$2.25M
AI expansion: $4M–$7M
National penetration: $7.5M–$22M annually
OEM Engine #2 — Veterinary AI
Elite performance animals: $500K–$1.2M
Specialty clinics: $3M–$7.5M
Global pet wearables: $12M–$25M+ annually
OEM Engine #3 — Haleon (Global Consumer Health)
Retail pilots: $2M–$5M
Global rollout: $15M–$35M
Mass-market wearables + subscriptions: $50M–$100M+ annually
These are phase-based rollouts already in motion, not distant hypotheticals.
Compared to this, the 2024–2025 financials are rounding errors.
3. Capital Factory Validation Makes the Past Irrelevant
Electrome is backed by Capital Factory, one of the most respected early-stage VC groups in the U.S.
Their involvement signals:
The tech is real
The platform is scalable
The hardware dependency on BIEL is locked in
Microcaps almost never get this halo — BIEL did.
Once institutional validation enters the picture, historical micro-revenues no longer matter — future cash flows do.
4. Float, Momentum, and AI Narrative = Re-Rating Catalysts
BIEL is gaining momentum — and it’s accelerating:
A historic 400% run - better than 99.9% of stocks (.0001 to .0005)
A vanishing float
A pending supply squeeze
This is the exact configuration that precedes violent re-ratings in microcaps.
And the AI narrative is the accelerant:
Electrome turns BIEL into a hot-sector AI hardware play.
This is why the market will price the future, not the past.
5. Profitability Is Within Reach — And the Model Is Ultra-Lean
BIEL has already demonstrated profitability:
Q3 2021 profit: $22,381 on $414,700 revenue
With COGS now dramatically lower and OEM volumes rising, the path to sustained profitability is short.
And the $40M tax-loss carryforward accelerates net profit conversion.
6. PPS Re-Rating Scenarios Make the Past Financials Meaningless
The market will re-rate based on OEM profit, not legacy device sales:
.001 — Technical breakout
.01 — Cash-flow positive (~$1.5M annual revenue)
.04 — $1M profit (P/E 1000)
.10 — $2.5M profit (P/E 1000)
$1.00 — After debt payoff + buyback
These valuations reflect the new business model, not the old one.
7. The Medvi Playbook — And Why It Maps Directly to BIEL/Electrome
Medvi went from a $20k idea to a $1.8B valuation by combining:
AI automation
healthcare workflows
data flywheels
scalable endpoints
BIEL/Electrome are now executing the same model, but with:
FDA-cleared hardware
a global distribution partner
VA deployments
celebrity investor validation
international adoption
a massive unmet need (chronic pain)
and a platform that scales like software
This is the strongest alignment of catalysts BIEL has seen in over a decade — and the closest real-world analog is Medvi’s $1.8B rise.
Electrome’s rise is BIEL’s inflection point.
The market hasn’t priced that in yet.
8. Publicity Is the Catalyst and Accelerant BIEL/Electrome Need
A rising PPS is not just a number — it is a media magnet.
BIEL: The Story Stock for 2026 @ PPS = .003
A move from .0001 to .003 is a 3,000% gain — larger than the 10-year percentage gains of Apple, Amazon, Netflix, Microsoft, Nvidia, Google, and others.
A move like that generates massive FREE PUBLICITY that would otherwise cost millions.
BIEL doesn’t need to spend a dollar on advertising.
A rising PPS creates the publicity for free.
The BIEL/Electrome narrative is tailor-made for media coverage:
FDA-cleared tech
AI-native therapeutics
celebrity investor
VA integration
global expansion
retail rollout
Make the PPS move — and the media will come to you.
Conclusion: The Old Book Is Closed — The New One Is a Multi-Vertical, AI-Native, VC-Validated Growth Engine
The 2024–2025 financials do not define BIEL — they are the last pages of the old story.
The new story is:
AI-native therapeutics
multi-industry OEM dominance
VC validation
global consumer-health integration
veterinary expansion
recurring hardware nodes
a closed-loop ecosystem
BIEL is no longer a $500K revenue company — it is a future multi-vertical OEM engine with $100M+ annual potential across its combined channels.
The past is irrelevant.
The future is asymmetric.
And the setup is even more asymmetric because BIEL is, functionally, a startup without startup risk:
five FDA clearances
validated manufacturing
VC-funded commercialization
zero early-stage burn
high-value patents pending (including vagus-nerve modulation)
and the first $40M profit is tax-free
This is the rare case where a microcap has the regulatory moat, the IP pipeline, and the VC-backed commercialization engine before the revenue inflection even begins.
The old book is closed.
The new one has just been released — and it’s a blockbuster.
The Medvi Playbook Is Repeating — But With a Bigger Market and Stronger Tailwinds
The conversation around BIEL is still stuck in the past — but the past is no longer relevant (except for the $40M+ tax-loss carryforward that makes the first $40M profit tax-free). The company that produced the 2024–2025 financials is not the company that exists today.
The pivot is complete.
The model has changed.
The market is only beginning to understand the scale of what’s unfolding.
This is the official beginning of the new story.
1. The 2024–2025 Financials Are Irrelevant — They Belong to the Old Book. Yes, 2025 revenue ticked up slightly and COGS dropped sharply, but:
These numbers reflect the pre-Electrome, pre-Haleon, pre-Veterinary era.
They are the last pages of the legacy standalone device seller model.
They have zero predictive value for the OEM future.
BIEL is no longer a consumer gadget company — it is now the exclusive hardware engine for an AI-native therapeutics ecosystem across:
human health
veterinary health
global consumer health
This is the Intel Inside transformation:
Electrome AI = the brain.
BIEL PEMF hardware = the engine.
The pivot just happened — so historical revenue is meaningless.
2. The OEM Future Is Measured in Millions — Not Thousands
BIEL now has three independent OEM engines, each with multi-million-dollar trajectories:
OEM Engine #1 — Human Health (Electrome)
PAINKILLER™ launch: $0.75M–$2.25M
AI expansion: $4M–$7M
National penetration: $7.5M–$22M annually
OEM Engine #2 — Veterinary AI
Elite performance animals: $500K–$1.2M
Specialty clinics: $3M–$7.5M
Global pet wearables: $12M–$25M+ annually
OEM Engine #3 — Haleon (Global Consumer Health)
Retail pilots: $2M–$5M
Global rollout: $15M–$35M
Mass-market wearables + subscriptions: $50M–$100M+ annually
These are phase-based rollouts already in motion, not distant hypotheticals.
Compared to this, the 2024–2025 financials are rounding errors.
3. Capital Factory Validation Makes the Past Irrelevant
Electrome is backed by Capital Factory, one of the most respected early-stage VC groups in the U.S.
Their involvement signals:
The tech is real
The platform is scalable
The hardware dependency on BIEL is locked in
Microcaps almost never get this halo — BIEL did.
Once institutional validation enters the picture, historical micro-revenues no longer matter — future cash flows do.
4. Float, Momentum, and AI Narrative = Re-Rating Catalysts
BIEL is gaining momentum — and it’s accelerating:
A historic 400% run - better than 99.9% of stocks (.0001 to .0005)
A vanishing float
A pending supply squeeze
This is the exact configuration that precedes violent re-ratings in microcaps.
And the AI narrative is the accelerant:
Electrome turns BIEL into a hot-sector AI hardware play.
This is why the market will price the future, not the past.
5. Profitability Is Within Reach — And the Model Is Ultra-Lean
BIEL has already demonstrated profitability:
Q3 2021 profit: $22,381 on $414,700 revenue
With COGS now dramatically lower and OEM volumes rising, the path to sustained profitability is short.
And the $40M tax-loss carryforward accelerates net profit conversion.
6. PPS Re-Rating Scenarios Make the Past Financials Meaningless
The market will re-rate based on OEM profit, not legacy device sales:
.001 — Technical breakout
.01 — Cash-flow positive (~$1.5M annual revenue)
.04 — $1M profit (P/E 1000)
.10 — $2.5M profit (P/E 1000)
$1.00 — After debt payoff + buyback
These valuations reflect the new business model, not the old one.
7. The Medvi Playbook — And Why It Maps Directly to BIEL/Electrome
Medvi went from a $20k idea to a $1.8B valuation by combining:
AI automation
healthcare workflows
data flywheels
scalable endpoints
BIEL/Electrome are now executing the same model, but with:
FDA-cleared hardware
a global distribution partner
VA deployments
celebrity investor validation
international adoption
a massive unmet need (chronic pain)
and a platform that scales like software
This is the strongest alignment of catalysts BIEL has seen in over a decade — and the closest real-world analog is Medvi’s $1.8B rise.
Electrome’s rise is BIEL’s inflection point.
The market hasn’t priced that in yet.
8. Publicity Is the Catalyst and Accelerant BIEL/Electrome Need
A rising PPS is not just a number — it is a media magnet.
BIEL: The Story Stock for 2026 @ PPS = .003
A move from .0001 to .003 is a 3,000% gain — larger than the 10-year percentage gains of Apple, Amazon, Netflix, Microsoft, Nvidia, Google, and others.
A move like that generates massive FREE PUBLICITY that would otherwise cost millions.
BIEL doesn’t need to spend a dollar on advertising.
A rising PPS creates the publicity for free.
The BIEL/Electrome narrative is tailor-made for media coverage:
FDA-cleared tech
AI-native therapeutics
celebrity investor
VA integration
global expansion
retail rollout
Make the PPS move — and the media will come to you.
Conclusion: The Old Book Is Closed — The New One Is a Multi-Vertical, AI-Native, VC-Validated Growth Engine
The 2024–2025 financials do not define BIEL — they are the last pages of the old story.
The new story is:
AI-native therapeutics
multi-industry OEM dominance
VC validation
global consumer-health integration
veterinary expansion
recurring hardware nodes
a closed-loop ecosystem
BIEL is no longer a $500K revenue company — it is a future multi-vertical OEM engine with $100M+ annual potential across its combined channels.
The past is irrelevant.
The future is asymmetric.
And the setup is even more asymmetric because BIEL is, functionally, a startup without startup risk:
five FDA clearances
validated manufacturing
VC-funded commercialization
zero early-stage burn
high-value patents pending (including vagus-nerve modulation)
and the first $40M profit is tax-free
This is the rare case where a microcap has the regulatory moat, the IP pipeline, and the VC-backed commercialization engine before the revenue inflection even begins.
The old book is closed.
The new one has just been released — and it’s a blockbuster.
